Florence Chaverneff, Ph.D.

Individuals administered ubrogepant for the acute treatment of migraine reported improvements in migraine-associated pain and functional disability, as well as general satisfaction with treatment.

The U.S. Food and Drug Administration is launching on April 25, 2019, its “Remove the Risk” campaign, aimed at promoting the safe disposal of unused opioids.

A series of 3 articles published in the Lancet is dedicated to highlighting the nature of current postsurgical pain management practices, including the use of peri- and postoperative opioids, that are thought to play a part in driving the opioid crisis.

Individuals with migraine who are obese may have reduced migraine frequency, lower pain intensity, shorter attack duration, and improved disability after losing weight.

Treating osteoarthritis in older patients with tramadol vs nonsteroidal anti-inflammatory drugs may be associated with an increased mortality rate during the year following treatment initiation.

Zydis® (rimegepat orally dissolving tablet) may provide fast relief from migraine-associated pain.

The law restricting access to medication-assisted treatment with methadone to opioid treatment programs may have contributed to reducing opioid-related overdose death rates in the United States.

Exercise professionals may act as “key supporters” of individuals with chronic pain.

A “Pain and Stress Management” program for the management of chronic pain, was found to be effective in alleviating pain, diminishing stress, promoting self-management of pain, and ameliorating general well-being.

Transcutaneous electrical nerve stimulation administered during physical activity may effectively alleviate fibromyalgia-associated pain, fatigue, and disease impact in women.